Encavis Valuation
Is ECV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ECV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ECV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ECV's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ECV?
Key metric: As ECV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ECV's PS Ratio? | |
|---|---|
| PS Ratio | 6.1x |
| Sales | €457.94m |
| Market Cap | €2.80b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 10.5x |
| Enterprise Value/EBITDA | 18.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ECV's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.6x | ||
HRPK 7C Solarparken | 2.4x | 2.2% | €156.6m |
TION Tion Renewables | 4.4x | n/a | €149.0m |
TION Tion Renewables | 4.1x | n/a | €139.5m |
ABO clearvise | 3.4x | 14.0% | €132.2m |
ECV Encavis | 6.1x | 8.4% | €2.8b |
Price-To-Sales vs Peers: ECV is expensive based on its Price-To-Sales Ratio (6.1x) compared to the peer average (3.6x).
Price to Sales Ratio vs Industry
How does ECV's PS Ratio compare vs other companies in the European Renewable Energy Industry?
| 13 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 13 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: ECV is expensive based on its Price-To-Sales Ratio (6.1x) compared to the European Renewable Energy industry average (2.6x).
Price to Sales Ratio vs Fair Ratio
What is ECV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.1x |
| Fair PS Ratio | 3x |
Price-To-Sales vs Fair Ratio: ECV is expensive based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €17.22 | €17.87 +3.8% | 4.9% | €20.30 | €17.50 | n/a | 9 |
| Nov ’25 | €17.13 | €17.87 +4.3% | 4.9% | €20.30 | €17.50 | n/a | 9 |
| Oct ’25 | €17.10 | €17.47 +2.2% | 7.9% | €20.30 | €13.90 | n/a | 11 |
| Sep ’25 | €17.00 | €17.47 +2.8% | 7.9% | €20.30 | €13.90 | n/a | 11 |
| Aug ’25 | €17.04 | €17.47 +2.5% | 7.9% | €20.30 | €13.90 | n/a | 11 |
| Jul ’25 | €17.03 | €17.47 +2.6% | 7.9% | €20.30 | €13.90 | n/a | 11 |
| Jun ’25 | €17.07 | €17.48 +2.4% | 7.6% | €20.30 | €13.90 | n/a | 12 |
| May ’25 | €16.90 | €17.60 +4.1% | 7.9% | €20.30 | €13.90 | n/a | 12 |
| Apr ’25 | €16.86 | €17.68 +4.9% | 8.1% | €20.30 | €13.90 | n/a | 12 |
| Mar ’25 | €10.84 | €17.69 +63.2% | 28.0% | €28.00 | €11.50 | n/a | 12 |
| Feb ’25 | €13.02 | €18.69 +43.6% | 25.6% | €28.00 | €11.50 | n/a | 12 |
| Jan ’25 | €15.39 | €19.25 +25.1% | 22.2% | €28.00 | €12.00 | n/a | 12 |
| Dec ’24 | €13.56 | €19.25 +42.0% | 22.2% | €28.00 | €12.00 | n/a | 12 |
| Nov ’24 | €12.06 | €20.82 +72.7% | 20.3% | €28.00 | €12.00 | €17.13 | 11 |
| Oct ’24 | €13.42 | €21.70 +61.8% | 15.4% | €28.00 | €17.00 | €17.10 | 10 |
| Sep ’24 | €13.86 | €21.96 +58.5% | 15.2% | €28.00 | €17.00 | €17.00 | 11 |
| Aug ’24 | €15.34 | €22.05 +43.8% | 14.8% | €28.00 | €17.00 | €17.04 | 11 |
| Jul ’24 | €14.99 | €22.33 +48.9% | 14.3% | €28.00 | €17.00 | €17.03 | 11 |
| Jun ’24 | €15.19 | €22.33 +47.0% | 14.3% | €28.00 | €17.00 | €17.07 | 11 |
| May ’24 | €15.61 | €22.41 +43.6% | 14.1% | €28.00 | €17.00 | €16.90 | 11 |
| Apr ’24 | €15.63 | €22.38 +43.2% | 14.2% | €28.00 | €17.00 | €16.86 | 11 |
| Mar ’24 | €17.53 | €22.72 +29.6% | 15.7% | €28.00 | €17.00 | €10.84 | 10 |
| Feb ’24 | €17.79 | €22.42 +26.0% | 16.6% | €28.00 | €17.00 | €13.02 | 9 |
| Jan ’24 | €18.62 | €23.73 +27.5% | 13.7% | €28.60 | €19.00 | €15.39 | 9 |
| Dec ’23 | €20.13 | €24.18 +20.1% | 15.6% | €30.00 | €19.00 | €13.56 | 9 |
| Nov ’23 | €19.15 | €24.11 +25.9% | 14.9% | €30.00 | €19.00 | €12.06 | 10 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Centrica
UK£6.4b
Operates as an integrated energy company in the United Kingdom, Ireland, Scandinavia, North America, and internationally.
CENB
UK£1.51
7D
4.0%
1Y
-11.3%
Magnora
NOK 1.6b
Operates as a renewable energy development company in Norway, Sweden, and the United States.
4SM
NOK 2.09
7D
-1.9%
1Y
-20.9%
China Resources Power Holdings
HK$90.4b
An investment holding company, invests in, develops, operates, and manages power plants and coal mines in the People’s Republic of China.
CRP
HK$2.15
7D
-0.2%
1Y
15.7%